Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• p53 is a crucial tumor suppressor regulating cell cycle arrest and apoptosis after DNA damage.
• Loss of p53 function is common in cancer, impairing DNA damage response.
• Understanding p53 mutations is key to developing effective cancer therapies.

Purpose of the Study:

• To investigate the impact of a specific p53 mutation (H179L) on cellular response to cisplatin.
• To analyze how this mutated p53 affects cell cycle progression and apoptosis.
• To determine if aberrant p53 influences chemosensitivity.

Main Methods:

• Stable expression of human p53 cDNA with H179L mutation in NIH3T3 cells.
• Treatment with the chemotherapeutic agent cisplatin.
• Flow cytometry, TUNEL assay, and caspase-3 activity assays to assess apoptosis and cell cycle arrest.
• Western blotting and kinase assays to evaluate protein expression and activity of cell cycle regulators (e.g., cdc2, cyclin B1, cyclin A, CDK2).

Main Results:

• Wild-type p53 cells underwent apoptosis with S- and G2 arrest after cisplatin, alongside increased Bax expression.
• H179L-p53 expressing cells showed S-phase arrest, decreased cdc2, cyclin B1, cyclin A expression, and reduced CDK2/cyclin A kinase activity.
• Cells expressing H179L-p53 exhibited earlier apoptosis than control cells, suggesting enhanced cisplatin chemosensitivity.
• Dominant-negative p53 influenced CDK complex activity and modified cellular response to genotoxicity.

Conclusions:

• The H179L p53 mutation alters cellular responses to genotoxic stress induced by cisplatin.
• Aberrant p53 impacts cell cycle regulation by affecting CDK complexes.
• This mutated p53 may enhance sensitivity to cisplatin chemotherapy, offering potential therapeutic insights.